Lapatinib Base CAS 231277-92-2 Puritas ≥99.0% (HPLC)

Description:

Nomen chemicum:Lapatinib Base

CAS: 231277-92-2

Puritas: ≥99.5% (HPLC)

Fere Alba aut lux Yellow Crystallina pulveris

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Lapatinib intermedia:

Lapatinib Base	CAS 231277-92-2
Lapatinib Ditosylate Monohydrate	CAS 388082-78-8
Sodium Methanesulfinate	CAS 20277-69-4
3-Chloro-4-(3-Fluorobenzyloxy)aniline	CAS 202197-26-0
2-Aminoethyl Methyl Sulfone Hydrochloridis	CAS 104458-24-4
4-Chloro-6-Iodoquinazoline	CAS 98556-31-1
6-Iodo-4-Hydroxyquinazoline	CAS 16064-08-7
5-Formyl-2-Acidi Furanboronic	CAS 27329-70-0
5-[4-[3-Chloro-4-(3-Fluorobenzyloxy)anilino]-6-Quinazolinyl]furan-2-Carboxaldehyde	CAS 231278-84-5

Chemical Properties:

Nomen chemicum	Lapatinib Base
Synonyma	Lapatinib;N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[(2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl]quinazolin-4-amine N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
CAS Number	231277-92-2
Stock Status	In Stock
Formulae hypotheticae	C29H26ClFN4O4S
M. Pondus	581.06
Liquescens punctum	141.0~149.0℃
Density	1.381±0.06 g/cm3
COA & MSDS	Praesto
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Fere Alba aut lux Yellow Crystallina pulveris
Lepidium sativum	IR;HPLC
Puritas / Analysis Methodus	≥99.0% (HPLC)
Liquescens punctum	141.0~149.0℃
Damnum in Siccatio	≤0.50%
Residere in Ignition	≤0.10%
Metalla gravia (ut Pb)	≤20ppm
Organicum volatile immunditias	Occurrit opus est
Substantiae cognatae
una immunditia	≤0.30%
Totalis immunditias	≤1.00%
Test Standard	Enterprise Standard
Fasciae vita	II annis cum rite condita
Consuetudinem	API, Curatio oris pro Cancro

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

231277-92-2 - Applicatio:

API (CAS: 231277-92-2)est therapia iaculis therapia of cancer pectus medicamentum, est inhibitor kinasus tyrosinus, potest efficaciter inhibere factorem receptoris humani epidermalis incrementi -1 (ErbB1) et factor incrementi epidermalis humani receptoris (ErbB2) activitatem kinasi tyrosini -2.Unicum est quod variis modis munus agere potest, ut cancer cellulae pectoris signum ad incrementum necessarium recipere non possit.Mechanismus actionis est inhibere intracellulares EGFR (ErbB-1) et HER2 (ErbB-2) ATP sites, ne phosphorylationem et activationem cellularum tumoris impediret et descensum ordinationem significandi ab EGFR (ErbB-1) et HER2 (ErbB-1) duo aggregata homogenea et heterogenea.Compositio (CAS: 231277-92-2) cum Capecitabine tractat aegros cum carcinomate provectio vel metastatico pectoris cum overexpressione receptoris humani epidermalis, cum anthracyclinis, paclitaxel et trastuzumab iam tractatis.De iudiciis clinicis demonstraverunt etiam efficaciter tractari HER2-type de aegris cancer cum resistentia Herceptin.

231277-92-2 - Indicationes:

Lapatinib in compositione cum Capecitabine apta est curationi carcinomatis progressi vel metastatici aegroti cum HER2(ErbB-2 overexpression) et praecedente curatione inter anthracyclinos, paclitaxel et trastuzumab.

231277-92-2 - Drug Interaction:

In vitro Lapatinib tabulae CYP3A4 et CYP2C8 in therapeuticis con- ceptionibus inhibere possunt, et maxime metabobilia sunt CYP3A4.medicinae quae hanc enzyme actionem inhibent signanter augere possunt sanguinem pharmacum pharmacum concentrationis Lapatinib.Ketoconazole, 0.2g singulis diebus, 2 vicibus/d, augere potest auc Lapatinib per 3~7 tempora et vitam dimidiam per 1.7 vicibus post 7 dies prorogare.Voluntarii sani ore CYP3A4 inducentes viva voce, 100 mg utrobique, bis in die, mutati sunt ad 200mg singulis vicibus post 3 dies, communicantes 17 dies bis in die.A. C. de Lapatinib% minui LXXII.Lapatinib terra oneraria est ad P-glycoprotein, et medicamenta quae glycoprotein inhibent sanguinem medicamentorum concentratione augere possunt.

Novum medicamentum pro Targeted Therapy de Cancro:

Novum medicamentum Lapatinib est iaculis justo pretium turpis a GlaxoSmithKline, UK.Inhibitor tyrosinus est qui efficaciter inhibere potest factorem receptoris humani epidermalis incrementi -1(ErbB1) et factor humanus epidermalis incrementi receptoris -2(ErbB2) kinasi activitatem tyrosinam.Unicum est quod variis modis fungi potest ut cancer cellulae pectoris signa ad incrementum necessaria recipere non possit.Mechanismus actionis est inhibere sites ATP EGFR(ErbB-1) et HER2(ErbB-2) in cellulis ne phosphorylationem et activationem cellularum tumoris et signa per deflexiones homogeneas et heterogeneas dimersas EGFR(ErbB obstruant. -1) and HER2(ErbB-1).Theraphim hypotheticum iaculis pro cancro mammae ad tractationem oncogenis pertinentia et expressio producta cognata ad eventum et progressionem cancri pectoris.Medicamenta hypothetica iaculis inhibent vel occidunt cellulas tumores obcludunt translationi signo in cellulis tumore vel cellulis affinibus ad mutationes in locutionibus e gene cellularum coercendis.die XIV mensis Martii, MMVII, US cibum et pharmacum administratio approbavit iuncturam lapatinib et xeloda (capecitabinae) ad curationem aegroti carcinomatis metastatici progressi vel cordis humani receptoris 2(ErbB2) receptoris epidermalis expressae et tractatae cum anthracyclinis, paclitaxel et trastuzumab .Orci probationes ostendunt hoc productum etiam effectus bonos clinicos habere pro aegris cancer pectoris HER2 qui medicamento resistentiam evolvit ad Herceptin Roche (Herceptin).lapatinib est novum medicamento iaculis anticancer.Potest agere in Her-1 et Her-2 scuta simul.Effectus biologicus huius modi agendi in prolificatione et incremento cellularum tuberculorum multo maior est quam unus tantum scopus.Sic dicta medicamenta therapeutica iaculis medicamenta spectant ad medicamenta quae aliquos receptores, gena vel clavos servo utentes ut scuta ad necem pertinentium cellas tumoris modo iaculis.